

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

CLCN7 RABBIT PAB

货号: S218507

产品全名: CLCN7 兔多抗

基因符号 HOD; CLC7; CLC-7; OPTA2; OPTB4; PPPIR63 UNIPROT ID: P51798 (Gene Accession - BC012737)

背景: The product of this gene belongs to the CLC chloride channel family of proteins. Chloride channels play important roles in the plasma membrane and in intracellular organelles. This gene encodes chloride channel 7. Defects in this gene are the cause of osteopetrosis autosomal recessive type 4 (OPTB4), also called infantile malignant osteopetrosis type 2 as well as the cause of autosomal dominant osteopetrosis type 2 (OPTA2), also called autosomal dominant Albers-Schonberg disease or marble disease autosomI dominant. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. OPTA2 is the most common form of osteopetrosis, occurring in adolescence or adulthood.

抗原: Fusion protein of human CLCN7

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 100-300;WB: 500-2000;ELISA: 5000-10000

种属反应性: Rabbit


克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism


储存和运输: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human esophagus cancer tissue using 218507(CLCN7 Antibody) at a dilution of 1/100(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with the fusion protein and then with 218507(Anti-CLCN7 Antibody) at dilution 1/100.



Gel: 6%SDS-PAGE, Lysate: 40 µg;

Lane 1-3: HepG2, A549, LOVO cell lysates;

Primary antibody: 218507(CLCN7 Antibody) at dilution 1/500;

Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000

dilution;

Exposure time: 2 minutes



Product Description

Pioneering GTPase and Oncogene Product Development since 2010